Value-Based Medtech Rides The Money-Go-Round Into 2016
The wider medtech industry saw only 2% growth in 2015, and medtechs in established markets face continued low growth for the next three to five years. The medtech M&A bonanza continued into 2015 and there is no end in sight in 2016 as manufacturers seek to augment and fine-tune portfolios to meet the new demands of payers and providers; longer term, there are signs of a change in the top global medtech rankings.
You may also be interested in...
Results from the CHAMPION study give St. Jude hope that its CardioMEMS system will stem the tide of heart failure.
Commissioner Robert Califf wants Janet Woodcock to improve food operations and processes, but lawmakers question whether she is the best overseer for the area.
Medtech Insight talked with XACT Robotics’ executive chairman Harel Gadot about plans for the FDA-cleared ACE robotic system and market opportunities. See what Gadot said about the market opportunity here.